NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TechTarget, Inc. (“TechTarget” or the “Company”) (NASDAQ: TTGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether TechTarget and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Pliant Therapeutics, Inc and its officers or directors [1] Company Developments - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [3] - Following this announcement, analysts from Wells Fargo and Citi downgraded Pliant, expressing uncertainty regarding the future of bexotegrast [3] Stock Performance - Pliant's stock price experienced a significant decline, falling by $4.72 per share, or 60.59%, closing at $3.07 per share on February 10, 2025 [4]

On this news, CarMax's stock price fell $13.61 per share, or 17%, to close at $66.45 per share on April 10, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomeran ...

On this news, TechTarget's stock price fell $1.04 per share, or 12.75%, to close at $7.12 per share on April 21, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Agilysys, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Agilysys reported third quarter revenue that fell below market expectations and its own guidance, leading to a significant downward revision of its full-year 2025 revenue outlook [3] - Following the disappointing earnings report, Agilysys's stock price dropped by $25.23 per share, or 20.04%, closing at $100.67 per share [3] Company Performance - The third quarter revenue of Agilysys was lower than anticipated, prompting a revision of the full-year revenue outlook [3] - CEO Ramesh Srinivasan acknowledged underestimating sales challenges related to the point-of-sale (POS) segment and indicated that the company could have performed better in hiring for implementation services [3] Legal Investigation - Pomerantz LLP, a firm specializing in corporate and securities class litigation, is leading the investigation into Agilysys for potential securities fraud [1][4] - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pliant Therapeutics, Inc is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop after pausing a clinical trial for its drug bexotegrast [1][3]. Company Developments - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [3]. - Following this announcement, analysts from Wells Fargo and Citi downgraded Pliant, indicating uncertainty regarding the future of bexotegrast [3]. Stock Performance - After the announcement of the trial pause, Pliant's stock price fell by $4.72 per share, representing a 60.59% decrease, closing at $3.07 per share on February 10, 2025 [4].

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PepGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 4, 2025, PepG ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Fortrea and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 3, ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Affirm Holdings, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On March 17, 2025, Klarna announced it would replace Affirm as the exclusive provider of Buy Now, Pay Later loans for Walmart, leading to a significant drop in Affirm's stock price by $6.38 per share, or 12.74%, closing at $43.70 per share on March 18, 2025 [3]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Open Lending Corp regarding potential securities fraud or unlawful business practices [1][3] Financial Performance - On March 17, 2025, Open Lending announced a delay in filing its annual report and postponed its Q4 and full-year 2024 earnings release, leading to a stock price drop of $0.82 per share, or 19.03%, closing at $3.49 per share on March 18, 2025 [3] - Following the filing of its annual report on March 31, 2025, Open Lending disclosed a larger-than-expected Q4 2024 net loss, attributed to a valuation allowance on deferred tax assets, resulting in a stock price decline of $1.59 per share, or 57.61%, closing at $1.17 per share on April 1, 2025 [4]